The content on this site is intended for healthcare professionals only
Dr Anant Ramaswamy speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.
He describes the background and design of this phase II trial, which evaluated the efficacy of capecitabine-irinotecan (CAPIRI) versus irinotecan alone in patients with advanced gall bladder cancer, who have progressed on first-line chemotherapy.
Dr Ramaswamy explains the results achieved in this study, and notes that no significant differences were found between the two arms - with regards to overall survival, progression-free survival and quality of life.
He discusses the potential clinical implications of these results and the next steps for this study.
Durable responses in aRCC, how do we optimise treatment?
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
